![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Aetna's recent decision to cover prescriptions for Arena's obesity drug Belviq is not an isolated event. Two important policy shifts at the federal level paved the way, and the policy shifts also bode well for more private insurance, Medicare and Medicaid coverage of prescription weight-loss drugs, including Belviq and Vivus, Inc.'s Qsymia. The shift in prescription coverage, a logical way to cut massive health costs caused by obesity-related disease and disability, is made possible by the FDA's approval of Belviq and Qsymia this summer. The full story is at: sandiegobiotechnology.com | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |